BioPorto Submits FDA Pre-Submission for Urine NGAL AKI Test After Positive Cut-Off Study
Event summary
- BioPorto submitted an FDA pre-submission package on March 31, 2026, seeking feedback on its Validation Study protocol for the U.S. adult urine NGAL program.
- The submission follows positive preliminary results from the U.S. adult urine NGAL Cut-off Study, reported on March 18, 2026.
- The Validation Study is a critical step toward achieving U.S. regulatory 510(k) clearance for the NGAL test.
- BioPorto's financial guidance for 2026 remains unchanged following this announcement.
The big picture
BioPorto's FDA pre-submission marks a strategic milestone in its efforts to expand the use of its NGAL biomarker test for Acute Kidney Injury (AKI) in the U.S. market. The test, which helps clinicians identify AKI risk earlier than current standards, aligns with broader industry trends toward precision diagnostics and early intervention in critical care. Success in the U.S. could significantly boost BioPorto's revenue and market presence, given the scale of the American healthcare ecosystem.
What we're watching
- Regulatory Alignment
- How the FDA's feedback on the Validation Study protocol will shape BioPorto's path to 510(k) clearance.
- Clinical Validation
- The pace at which BioPorto can advance the Validation Study following FDA guidance.
- Market Expansion
- Whether successful U.S. clearance will accelerate BioPorto's commercialization efforts for the NGAL test.
Related topics